Shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus target price of $47.00 for the company and are forecasting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also assigned Opiant Pharmaceuticals an industry rank of 93 out of 256 based on the ratings given to related companies.
Separately, Cantor Fitzgerald set a $42.00 price target on shares of Opiant Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, September 28th.
Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings results on Wednesday, November 7th. The technology company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.21). Opiant Pharmaceuticals had a negative net margin of 187.13% and a negative return on equity of 175.03%. The company had revenue of $4.37 million during the quarter, compared to analyst estimates of $4.70 million. Equities analysts predict that Opiant Pharmaceuticals will post -4.59 EPS for the current fiscal year.
In other news, CEO Roger Crystal sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $13.34, for a total value of $667,000.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Phil Skolnick sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 4th. The shares were sold at an average price of $13.76, for a total transaction of $137,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,142 shares of company stock worth $906,791. 37.92% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Stonepine Capital Management LLC bought a new position in Opiant Pharmaceuticals in the 3rd quarter valued at approximately $3,320,000. Vanguard Group Inc raised its holdings in Opiant Pharmaceuticals by 25.1% in the 3rd quarter. Vanguard Group Inc now owns 105,432 shares of the technology company’s stock valued at $1,883,000 after buying an additional 21,151 shares during the last quarter. Vanguard Group Inc. raised its holdings in Opiant Pharmaceuticals by 25.1% in the 3rd quarter. Vanguard Group Inc. now owns 105,432 shares of the technology company’s stock valued at $1,883,000 after buying an additional 21,151 shares during the last quarter. Granite Point Capital Management L.P. bought a new position in Opiant Pharmaceuticals in the 3rd quarter valued at approximately $1,340,000. Finally, Northern Trust Corp bought a new position in Opiant Pharmaceuticals in the 2nd quarter valued at approximately $350,000. Institutional investors and hedge funds own 17.01% of the company’s stock.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Read More: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.